Apimeds Pharmaceuticals US (APUS) Assets Average (2025)

Apimeds Pharmaceuticals US (APUS) reported Assets Average of $86.7 million for Q4 2025, up 776.07% quarter-over-quarter from $9.9 million in Q3 2025.

Apimeds Pharmaceuticals US (APUS) Assets Average (2025) Analysis & Trends

Apimeds Pharmaceuticals US has reported Assets Average for 1 years, with the latest figure at $86.7 million in Q4 2025.

For the quarter ending Q4 2025, Assets Average changed N/A year-over-year to $86.7 million; the trailing twelve-month figure through Dec 2025 stood at $86.7 million (changed N/A YoY), and the FY2025 full-year result was $82.1 million, up 37634.85% from the prior year.
Assets Average for Q4 2025 stood at $86.7 million, up from $9.9 million in the prior quarter.
The five-year high for Assets Average was $86.7 million in Q4 2025, with the low at $136480.5 in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Assets Avg. (Qtr)
1	Teva Pharmaceutical Industries	39.72 Bn	35.98 Bn	1.97 Bn	40.39 Bn
2	Zoetis	34.61 Bn	32.67 Bn	1.62 Bn	15.32 Bn
3	United Therapeutics	24.07 Bn	21.91 Bn	648.10 Mn	7.30 Bn
4	Aurora Cannabis	16.98 Bn	16.91 Bn	33.43 Mn	552.96 Mn
5	Neurocrine Biosciences	16.64 Bn	15.32 Bn	800.70 Mn	4.77 Bn
6	Elanco Animal Health	12.19 Bn	11.76 Bn	785.00 Mn	13.29 Bn
7	Alkermes	7.37 Bn	6.86 Bn	-116.06 Mn	3.37 Bn
8	Hims & Hers Health	6.62 Bn	5.87 Bn	396.79 Mn	2.21 Bn
9	Lantheus Holdings	6.47 Bn	5.97 Bn	230.92 Mn	2.29 Bn
10	Apimeds Pharmaceuticals US	13.93 Mn	10.29 Mn	-	86.72 Mn

Download Data